gemfibrozil has been researched along with Elevated Cholesterol in 97 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thirty middle-aged men selected according to their low density lipoprotein-cholesterol (LDL-C) > or = 160 and < or = 240 mg/dl and borderline hypertriglyceridemia (110-220 mg/dl) after at least one month of a lipid-lowering diet received gemfibrozil (600 mg bid) or simvastatin (20 mg qd) and the corresponding placebo." | 9.09 | Post-prandial effects of gemfibrozil vs simvastatin in hypercholesterolemic subjects with borderline hypertriglyceridemia. ( Cattin, L; Donega, P; Fellin, R; Fonda, M; Gasparrini, S; Marotta, G; Passaro, A; Pauciullo, P; Piliego, T; Vigna, GB; Zanca, R, 1999) |
| "In patients with primary hypercholesterolemia, lovastatin alone or in combination with cholestyramine was more effective than gemfibrozil alone or in combination with cholestyramine to lower total cholesterol and LDL-cholesterol." | 9.08 | [Multicenter comparative study on safety, tolerance, and effectiveness of lovastatin combined or not with cholestyramine, and gemfibrozil combined or not with cholestyramine in the treatment of primary hypercholesterolemia]. ( Aranda, JL; del Palacio, A; Jover, E; Nogués, X; Rubiés-Prat, J, 1996) |
| "To compare the lipid-lowering efficacies of simvastatin and gemfibrozil in NIDDM patients with combined (mixed) hyperlipidemia (CHL) or isolated hypercholesterolemia (IHC)." | 9.08 | Treatment of hypercholesterolemia and combined hyperlipidemia with simvastatin and gemfibrozil in patients with NIDDM. A multicenter comparison study. ( Helve, E; Ilmonen, M; Kaarsalo, E; Kilkki, E; Laakso, M; Saltevo, J; Tikkanen, MJ, 1998) |
| "This study compared the efficacy and safety of pravastatin and gemfibrozil in the treatment of primary hypercholesterolemia." | 9.07 | Pravastatin vs gemfibrozil in the treatment of primary hypercholesterolemia. The Italian Multicenter Pravastatin Study I. ( Arca, M; Avellone, G; Avogaro, P; Baggio, G; Bittolo Bon, G; Bompiani, GD; Capurso, A; Cattin, L; Crepaldi, G; D'Alŏ, G, 1991) |
| "The efficacy and tolerability of lovastatin and gemfibrozil were compared in a randomized double-blind 12-week study including 182 patients with primary hypercholesterolemia, from 7 hospitals in Spain." | 9.07 | A multicenter double-blind study comparing lovastatin and gemfibrozil in the treatment of primary hypercholesterolemia. ( Aguirre, C; Anglada, J; Anguita, M; Azanza, JR; Barcina, C; Fabiani, F; Plaza, L; Soriguer, F; Vallés, F, 1991) |
| "A total of 123 patients with primary hypercholesterolemia were randomized on a 2:1 ratio to receive either fluvastatin at 20 mg once daily at night (n = 82) or gemfibrozil at 600 mg twice daily (n = 41) in a double-blind, double-dummy comparison of the effects on plasma lipid parameters and tolerability over 8 weeks." | 9.07 | Comparison of lipid-lowering effects of low-dose fluvastatin and conventional-dose gemfibrozil in patients with primary hypercholesterolemia. ( Betteridge, DJ; Durrington, PN; Fairhurst, GJ; Jackson, G; McEwan, MS; McInnes, GT; Miller, JP; Mir, MA; Reckless, JP; Rees-Jones, DI, 1994) |
| "A randomized, multicenter, double-blind, prospective, 18-week comparison of lovastatin with gemfibrozil was performed to compare their efficacy and tolerability in adults with types IIa and IIb primary hypercholesterolemia." | 9.07 | A comparison between lovastatin and gemfibrozil in the treatment of primary hypercholesterolemia. ( D'Agostino, LC; D'Agostino, RB; Kannel, WB; Stepanians, MN, 1992) |
| "To compare the efficacy and safety of pravastatin, gemfibrozil, combined therapy, and placebo in the treatment of hypercholesterolemia." | 9.07 | Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia. ( Angelin, B; Berglund, L; Bergman, M; Bondjers, G; Carlsson, A; Lindén, T; Miettinen, T; Odman, B; Olofsson, SO; Wiklund, O, 1993) |
| "The hypolipidemic effect of gemfibrozil in severe hypercholesterolemia is not well established." | 9.07 | Comparative study of a microporous cholestyramine analogue (filicol) and gemfibrozil for treatment of severe primary hypercholesterolemia. Short- and long-term results. ( Bertomeu, A; Casals, E; Cusó, E; Ros, E; Sanllehy, C; Zambón, D, 1991) |
| "To compare the effects of lovastatin and gemfibrozil in patients with primary hyperlipidemias." | 9.07 | [Comparison between lovastatin and gemfibrozil in treatment of primary hyperlipidemias]. ( Batlouni, M; Bertolami, MC; Bismarck, ZF; Faludi, AA; Martinez, TL; Melo, RS; Pinto, LE, 1991) |
| "In a randomized, double-blind five-year trial, we tested the efficacy of simultaneously elevating serum levels of high-density lipoprotein (HDL) cholesterol and lowering levels of non-HDL cholesterol with gemfibrozil in reducing the risk of coronary heart disease in 4081 asymptomatic middle-aged men (40 to 55 years of age) with primary dyslipidemia (non-HDL cholesterol greater than or equal to 200 mg per deciliter [5." | 9.06 | Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. ( Elo, O; Frick, MH; Haapa, K; Heinonen, OP; Heinsalmi, P; Helo, P; Huttunen, JK; Kaitaniemi, P; Koskinen, P; Manninen, V, 1987) |
| "29 patients with primary hypercholesterolemia were treated for 8 weeks each with either bezafibrate (200 mg t." | 9.06 | Effects of bezafibrate and gemfibrozil on serum lipoproteins in primary hypercholesterolemia. ( Weisweiler, P, 1988) |
| "A randomized, double-blind 12-week comparison of lovastatin and gemfibrozil in the treatment of patients with primary hypercholesterolemia with normal or moderately elevated triglycerides was performed in 334 patients from 19 centers in Finland." | 9.06 | Comparison between lovastatin and gemfibrozil in the treatment of primary hypercholesterolemia: the Finnish Multicenter Study. ( Helve, E; Jäättelä, A; Kaarsalo, E; Lehtonen, A; Malbecq, W; Oksa, H; Pääkkönen, P; Salmi, J; Tikkanen, MJ; Veharanta, T, 1988) |
| "02) reduction in the incidence of cardiac end points (myocardial infarction and cardiac death) with the use of gemfibrozil compared with the use of a placebo in dyslipidemic middle-aged men." | 9.06 | Reduction in Q wave myocardial infarctions with gemfibrozil in the Helsinki Heart Study. ( Frick, MH; Heinonen, OP; Huttunen, JK; Koskinen, P; Manninen, V; Mänttäri, M; Romo, M, 1990) |
| "Gemfibrozil is a fibrate drug." | 7.77 | [Evaluation of the therapeutic efficacy of pravastatin in monothereapy and in association with gemfibrozil in hypercholesterolemia associated with moderate hyperglyceridemia]. ( Ambrosio, G; Chiariello, M; Lepore, S; Napoli, C, 1992) |
| "The Food and Drug Administration documents the receipt of 12 case reports of severe myopathy or rhabdomyolysis associated with concomitant use of lovastatin and gemfibrozil, including 10 voluntary postmarketing, and 2 required, reports." | 7.68 | Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. ( Gross, TP; Pierce, LR; Wysowski, DK, 1990) |
| "Gemfibrozil (n = 69) was given at 900 mg q." | 6.67 | [Comparison of the efficacy between simvastatin and gemfibrozil in primary hypercholesterolemia]. ( Baigts, F; Devulder, B; Lecerf, JM; Luc, G, 1993) |
| "Treatment with simvastatin or gemfibrozil in hypertensive patients in hydrochlorothiazide monotherapy can reduce total cholesterol and LDL-cholesterol plasma levels, while significantly increasing HDL plasma levels compared to placebo." | 6.67 | [Simvastatin versus gemfibrozil in the treatment of primary hypercholesterolemia in hypertensive patients treated with hydrochlorothiazide]. ( Bentivoglio, M; Berioli, S; Conti, R; Corea, L; Osanna, RA; Savino, K; Zollino, L, 1990) |
| "Pravastatin lead to an increase of the HDL concentration of approximately 8%, gemfibrocil to approximately 13%, whilst cholestyramine alone did not change this lipid fraction." | 6.67 | [Pravastatin, cholestyramine and gemfibrozil in long-term therapy of primary hypercholesterolemia. An open randomized comparative study]. ( Dammann, HG; Ditschuneit, H; Ditschuneit, HH; Dreyer, M, 1991) |
| "However, anemia and leukopenia are known side effects of gemfibrozil." | 5.56 | Gemfibrozil Induces Anemia, Leukopenia and Reduces Hematopoietic Stem Cells via PPAR-α in Mice. ( Araujo, RC; Arruda, AC; Budu, A; Estrela, GR; Fock, RA; Freitas-Lima, LC; Paredes-Gamero, EJ; Perilhão, MS; Torquato, HFV; Wasinski, F, 2020) |
| " These differences may be due to interactions between genetic and environmental factors that effect drug bioavailability or the capacity of the lipid-regulating enzyme and receptor targets to be affected." | 5.30 | Lack of interaction of apolipoprotein E phenotype with the lipoprotein response to lovastatin or gemfibrozil in patients with primary hypercholesterolemia. ( Ballesta, AM; Casals, E; Ojuel, J; Rodriguez-Villar, C; Ros, E; Sanllehy, C; Zambón, D, 1998) |
| "Thirty middle-aged men selected according to their low density lipoprotein-cholesterol (LDL-C) > or = 160 and < or = 240 mg/dl and borderline hypertriglyceridemia (110-220 mg/dl) after at least one month of a lipid-lowering diet received gemfibrozil (600 mg bid) or simvastatin (20 mg qd) and the corresponding placebo." | 5.09 | Post-prandial effects of gemfibrozil vs simvastatin in hypercholesterolemic subjects with borderline hypertriglyceridemia. ( Cattin, L; Donega, P; Fellin, R; Fonda, M; Gasparrini, S; Marotta, G; Passaro, A; Pauciullo, P; Piliego, T; Vigna, GB; Zanca, R, 1999) |
| "In patients with primary hypercholesterolemia, lovastatin alone or in combination with cholestyramine was more effective than gemfibrozil alone or in combination with cholestyramine to lower total cholesterol and LDL-cholesterol." | 5.08 | [Multicenter comparative study on safety, tolerance, and effectiveness of lovastatin combined or not with cholestyramine, and gemfibrozil combined or not with cholestyramine in the treatment of primary hypercholesterolemia]. ( Aranda, JL; del Palacio, A; Jover, E; Nogués, X; Rubiés-Prat, J, 1996) |
| " We have evaluated a combination of medical treatment with Gemfibrozil (600 mg bid) and a Mediterranean diet for 2 months in 15 patients with both hypercholesterolemia (> 240 mg/dl) and high levels of Lp(a) (> 30 mg/dl)." | 5.08 | Gemfibrozil and Mediterranean diet for patients with high plasma levels of lipoprotein [Lp(a)] and cholesterol--pilot study. ( Ardia, A; Baiardi, A; Civalleri, D; Gianotti, A; Simoni, G, 1995) |
| " Six hundred and twelve patients with postdiet LDL cholesterol (LDL-C) levels in the range of 190-230 mg/dl (or 160-230 mg/dl for those with coronary heart disease or two or more coronary risk factors) were randomized to a stepped-care regimen (initial treatment with niacin followed by other agents if needed) or to initial use of lovastatin, an HMG-CoA reductase inhibitor." | 5.08 | A randomized trial to assess effectiveness and cost in clinical practice: rationale and design of the Cholesterol Reduction Intervention Study (CRIS). ( Benson, VV; Borok, GM; Dudl, RJ; Epstein, A; Epstein, RS; Heys, JF; Menzin, J; Oster, G; Quinn, V, 1995) |
| " Patients with moderate hypercholesterolemia (n = 147) were randomized to pravastatin 40 mg o." | 5.08 | Insoluble complex formation between LDL and arterial proteoglycans in relation to serum lipid levels and effects of lipid lowering drugs. ( Bondjers, G; Camejo, G; Wiklund, O; Wright, I, 1996) |
| "To compare the effects of gemfibrozil and lovastatin in patients with hypercholesterolemia and increased lipoprotein(a) [Lp(a)] levels." | 5.08 | [Gemfibrozil reduces elevated lipoprotein (a) levels in hypercholesterolemic patients]. ( Chamone, D; da Luz, PL; Mansur, AP; Pileggi, F; Ramires, JA; Solimene, MC; Spósito, AC, 1997) |
| "To compare the lipid-lowering efficacies of simvastatin and gemfibrozil in NIDDM patients with combined (mixed) hyperlipidemia (CHL) or isolated hypercholesterolemia (IHC)." | 5.08 | Treatment of hypercholesterolemia and combined hyperlipidemia with simvastatin and gemfibrozil in patients with NIDDM. A multicenter comparison study. ( Helve, E; Ilmonen, M; Kaarsalo, E; Kilkki, E; Laakso, M; Saltevo, J; Tikkanen, MJ, 1998) |
| "This study compared the efficacy and safety of pravastatin and gemfibrozil in the treatment of primary hypercholesterolemia." | 5.07 | Pravastatin vs gemfibrozil in the treatment of primary hypercholesterolemia. The Italian Multicenter Pravastatin Study I. ( Arca, M; Avellone, G; Avogaro, P; Baggio, G; Bittolo Bon, G; Bompiani, GD; Capurso, A; Cattin, L; Crepaldi, G; D'Alŏ, G, 1991) |
| "The hypolipidemic effect of gemfibrozil in severe hypercholesterolemia is not well established." | 5.07 | Comparative study of a microporous cholestyramine analogue (filicol) and gemfibrozil for treatment of severe primary hypercholesterolemia. Short- and long-term results. ( Bertomeu, A; Casals, E; Cusó, E; Ros, E; Sanllehy, C; Zambón, D, 1991) |
| "To compare the efficacy and safety of pravastatin, gemfibrozil, combined therapy, and placebo in the treatment of hypercholesterolemia." | 5.07 | Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia. ( Angelin, B; Berglund, L; Bergman, M; Bondjers, G; Carlsson, A; Lindén, T; Miettinen, T; Odman, B; Olofsson, SO; Wiklund, O, 1993) |
| "A total of 123 patients with primary hypercholesterolemia were randomized on a 2:1 ratio to receive either fluvastatin at 20 mg once daily at night (n = 82) or gemfibrozil at 600 mg twice daily (n = 41) in a double-blind, double-dummy comparison of the effects on plasma lipid parameters and tolerability over 8 weeks." | 5.07 | Comparison of lipid-lowering effects of low-dose fluvastatin and conventional-dose gemfibrozil in patients with primary hypercholesterolemia. ( Betteridge, DJ; Durrington, PN; Fairhurst, GJ; Jackson, G; McEwan, MS; McInnes, GT; Miller, JP; Mir, MA; Reckless, JP; Rees-Jones, DI, 1994) |
| "A randomized, multicenter, double-blind, prospective, 18-week comparison of lovastatin with gemfibrozil was performed to compare their efficacy and tolerability in adults with types IIa and IIb primary hypercholesterolemia." | 5.07 | A comparison between lovastatin and gemfibrozil in the treatment of primary hypercholesterolemia. ( D'Agostino, LC; D'Agostino, RB; Kannel, WB; Stepanians, MN, 1992) |
| "In a contribution to a prolonged multicenter study 15 patients with primary hypercholesterolemia were treated with simvastatin, a competitive inhibitor of HMG-CoA reductase." | 5.07 | Significant increase of high-density lipoprotein2-cholesterol under prolonged simvastatin treatment. ( Neuman, HR; Neuman, J; Neuman, MP, 1991) |
| "The efficacy and tolerability of lovastatin and gemfibrozil were compared in a randomized double-blind 12-week study including 182 patients with primary hypercholesterolemia, from 7 hospitals in Spain." | 5.07 | A multicenter double-blind study comparing lovastatin and gemfibrozil in the treatment of primary hypercholesterolemia. ( Aguirre, C; Anglada, J; Anguita, M; Azanza, JR; Barcina, C; Fabiani, F; Plaza, L; Soriguer, F; Vallés, F, 1991) |
| "To compare the effects of lovastatin and gemfibrozil in patients with primary hyperlipidemias." | 5.07 | [Comparison between lovastatin and gemfibrozil in treatment of primary hyperlipidemias]. ( Batlouni, M; Bertolami, MC; Bismarck, ZF; Faludi, AA; Martinez, TL; Melo, RS; Pinto, LE, 1991) |
| "A variety of double-blind studies have compared the efficacy of hydroxymethylglutaryl coenzyme A reductase inhibitors (lovastatin and simvastatin) with that of control agents (cholestyramine, fibrates and probucol) in patients with type IIA or IIB primary hypercholesterolemia." | 5.06 | Hydroxymethylglutaryl coenzyme A reductase inhibitors as monotherapy in the treatment of hypercholesterolemia. ( Shapiro, DR; Walker, JF, 1990) |
| " In a double-blind, parallel, randomized study, lovastatin and gemfibrozil were compared in 102 diabetic patients with primary hypercholesterolemia; two-thirds of the patients were treated with oral hypoglycemic agents and one-third received diet therapy alone for their diabetes." | 5.06 | Comparison of the effects of lovastatin and gemfibrozil on lipids and glucose control in non-insulin-dependent diabetes mellitus. ( Goldberg, R; La Belle, P; Ronca, P; Zupkis, R, 1990) |
| "02) reduction in the incidence of cardiac end points (myocardial infarction and cardiac death) with the use of gemfibrozil compared with the use of a placebo in dyslipidemic middle-aged men." | 5.06 | Reduction in Q wave myocardial infarctions with gemfibrozil in the Helsinki Heart Study. ( Frick, MH; Heinonen, OP; Huttunen, JK; Koskinen, P; Manninen, V; Mänttäri, M; Romo, M, 1990) |
| "In a randomized, double-blind five-year trial, we tested the efficacy of simultaneously elevating serum levels of high-density lipoprotein (HDL) cholesterol and lowering levels of non-HDL cholesterol with gemfibrozil in reducing the risk of coronary heart disease in 4081 asymptomatic middle-aged men (40 to 55 years of age) with primary dyslipidemia (non-HDL cholesterol greater than or equal to 200 mg per deciliter [5." | 5.06 | Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. ( Elo, O; Frick, MH; Haapa, K; Heinonen, OP; Heinsalmi, P; Helo, P; Huttunen, JK; Kaitaniemi, P; Koskinen, P; Manninen, V, 1987) |
| "A randomized, double-blind 12-week comparison of lovastatin and gemfibrozil in the treatment of patients with primary hypercholesterolemia with normal or moderately elevated triglycerides was performed in 334 patients from 19 centers in Finland." | 5.06 | Comparison between lovastatin and gemfibrozil in the treatment of primary hypercholesterolemia: the Finnish Multicenter Study. ( Helve, E; Jäättelä, A; Kaarsalo, E; Lehtonen, A; Malbecq, W; Oksa, H; Pääkkönen, P; Salmi, J; Tikkanen, MJ; Veharanta, T, 1988) |
| "29 patients with primary hypercholesterolemia were treated for 8 weeks each with either bezafibrate (200 mg t." | 5.06 | Effects of bezafibrate and gemfibrozil on serum lipoproteins in primary hypercholesterolemia. ( Weisweiler, P, 1988) |
| "Gemfibrozil is a fibrate drug." | 3.77 | [Evaluation of the therapeutic efficacy of pravastatin in monothereapy and in association with gemfibrozil in hypercholesterolemia associated with moderate hyperglyceridemia]. ( Ambrosio, G; Chiariello, M; Lepore, S; Napoli, C, 1992) |
| " We report a case of fatal rhabdomyolysis caused by the combination of simvastatin and gemfibrozil." | 3.71 | Fatal rhabdomyolysis caused by lipid-lowering therapy. ( Federman, DG; Hussain, F; Walters, AB, 2001) |
| "Experimental hypercholesterolemia and its modulation by some natural dietary supplements (pectin, garlic and ginseng) and by the drug gemfibrozil were studied." | 3.70 | Study of the hypolipidemic properties of pectin, garlic and ginseng in hypercholesterolemic rabbits. ( Gad, MZ; Hamdy, MA; Ismail, MF, 1999) |
| "(1) In primary prevention trials, pravastatin and lovastatin prevented myocardial infarction and had a positive risk-benefit ratio in men with LDL-cholesterol values exceeding 4." | 3.70 | Cholesterol-lowering drugs. Some drugs with demonstrated efficacy but different benefits in primary and secondary prevention. ( , 1999) |
| "A retrospective chart analysis of 200 consecutive, cyclosporine-treated, renal allograft recipients, transplanted between January 1988 and June 1992, was conducted to determine the incidence of and the etiologic variables for post-transplant hypercholesterolemia." | 3.69 | Post-transplant hyperlipidemia: risk factors and response to dietary modification and gemfibrozil therapy. ( Aridge, D; Bastani, B; Garvin, PJ; Heisler, T; Lindsey, L; Puntney, G; Robinson, S; Solomon, H, 1995) |
| "The Food and Drug Administration documents the receipt of 12 case reports of severe myopathy or rhabdomyolysis associated with concomitant use of lovastatin and gemfibrozil, including 10 voluntary postmarketing, and 2 required, reports." | 3.68 | Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. ( Gross, TP; Pierce, LR; Wysowski, DK, 1990) |
| " In 55 patients (20 on HD, 13 on CAPD and 22 NDCRF) with severe hypertriglyceridemia or diminished HDL cholesterol gemfibrozil 300 mg b." | 3.68 | Lipid abnormalities in chronic uremic patients. Response to treatment with gemfibrozil. ( Dardamanis, MA; Elisaf, MS; Papagalanis, ND; Siamopoulos, KC, 1993) |
| "Lovastatin reduced pretreatment levels of atherogenic and triglyceride-rich lipoprotein components and slowed post-treatment increases compared with no drug therapy." | 2.68 | Changes in plasma lipid and apolipoprotein levels between heparin-induced extracorporeal low-density lipoprotein precipitation (HELP) treatments. ( Alaupovic, P; Dudley, VS; Knight-Gibson, C; Lane, DM; Laughlin, LO, 1995) |
| "Pravastatin lead to an increase of the HDL concentration of approximately 8%, gemfibrocil to approximately 13%, whilst cholestyramine alone did not change this lipid fraction." | 2.67 | [Pravastatin, cholestyramine and gemfibrozil in long-term therapy of primary hypercholesterolemia. An open randomized comparative study]. ( Dammann, HG; Ditschuneit, H; Ditschuneit, HH; Dreyer, M, 1991) |
| "Treatment with simvastatin or gemfibrozil in hypertensive patients in hydrochlorothiazide monotherapy can reduce total cholesterol and LDL-cholesterol plasma levels, while significantly increasing HDL plasma levels compared to placebo." | 2.67 | [Simvastatin versus gemfibrozil in the treatment of primary hypercholesterolemia in hypertensive patients treated with hydrochlorothiazide]. ( Bentivoglio, M; Berioli, S; Conti, R; Corea, L; Osanna, RA; Savino, K; Zollino, L, 1990) |
| "Gemfibrozil (n = 69) was given at 900 mg q." | 2.67 | [Comparison of the efficacy between simvastatin and gemfibrozil in primary hypercholesterolemia]. ( Baigts, F; Devulder, B; Lecerf, JM; Luc, G, 1993) |
| " The patients were treated with gemfibrozil on a constant dosage (range 900-1200 mg/day) during the entire trial." | 2.66 | Guar gum and gemfibrozil--an effective combination in the treatment of hypercholesterolaemia. ( Aro, A; Manninen, V; Silvasti, M; Tuomilehto, J; Uusitupa, M, 1989) |
| "Furthermore, hypertriglyceridemia is now recognized as an independent risk factor for coronary artery disease." | 2.43 | Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism. ( Duriez, P; Fruchart, JC, 2006) |
| "Children have been tested and treated for hypercholesterolemia for more than 30 years." | 2.41 | Statins in children: what do we know and what do we need to do? ( Black, DM, 2001) |
| "Niacin was the most efficient agent for reducing low-density lipoprotein cholesterol levels, having an average cost over 5 years of $139 per percent reduction in low-density lipoprotein cholesterol level." | 2.38 | Reducing high blood cholesterol level with drugs. Cost-effectiveness of pharmacologic management. ( Eisenberg, JM; Glick, H; Jacobson, TA; Kinosian, B; Koffer, H; Schulman, KA; Willian, MK, 1990) |
| "However, anemia and leukopenia are known side effects of gemfibrozil." | 1.56 | Gemfibrozil Induces Anemia, Leukopenia and Reduces Hematopoietic Stem Cells via PPAR-α in Mice. ( Araujo, RC; Arruda, AC; Budu, A; Estrela, GR; Fock, RA; Freitas-Lima, LC; Paredes-Gamero, EJ; Perilhão, MS; Torquato, HFV; Wasinski, F, 2020) |
| "The drug elevated cholesterol 7 alpha-hydroxylase activity and mRNA abundance and acyl-CoA cholesterol acyltransferase activity in the liver, but did not influence low-density lipoprotein receptor mRNA level in the liver." | 1.30 | Gemfibrozil reduces non-high-density lipoprotein cholesterol in exogenously hypercholesterolemic (ExHC) rats fed a high-cholesterol diet. ( Imaizumi, K; Nagao, K; Nakagiri, H; Sakono, M; Sato, M; Yoshida, S, 1998) |
| " These differences may be due to interactions between genetic and environmental factors that effect drug bioavailability or the capacity of the lipid-regulating enzyme and receptor targets to be affected." | 1.30 | Lack of interaction of apolipoprotein E phenotype with the lipoprotein response to lovastatin or gemfibrozil in patients with primary hypercholesterolemia. ( Ballesta, AM; Casals, E; Ojuel, J; Rodriguez-Villar, C; Ros, E; Sanllehy, C; Zambón, D, 1998) |
| "Hyperlipidemia due to standard immunosuppressive agents occurs commonly following solid organ transplantation." | 1.30 | Lack of left ventricular dysfunction associated with sustained exposure to hyperlipidemia following lung transplantation. ( Kesten, S; Maurer, J; Mayne, L; Scavuzzo, M, 1997) |
| " Most of these drugs have side effects which, in the elderly, may necessitate lower dosing than usual." | 1.27 | Treating hyperlipidemia, Part III: Drug therapy. ( Brown, WV; Karmally, W; Smith, DA, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 16 (16.49) | 18.7374 |
| 1990's | 63 (64.95) | 18.2507 |
| 2000's | 15 (15.46) | 29.6817 |
| 2010's | 2 (2.06) | 24.3611 |
| 2020's | 1 (1.03) | 2.80 |
| Authors | Studies |
|---|---|
| Estrela, GR | 1 |
| Arruda, AC | 1 |
| Torquato, HFV | 1 |
| Freitas-Lima, LC | 1 |
| Perilhão, MS | 1 |
| Wasinski, F | 1 |
| Budu, A | 1 |
| Fock, RA | 1 |
| Paredes-Gamero, EJ | 1 |
| Araujo, RC | 1 |
| Bertolotti, M | 1 |
| Del Puppo, M | 1 |
| Gabbi, C | 1 |
| Corna, F | 1 |
| Carulli, L | 1 |
| Pellegrini, E | 1 |
| Zambianchi, L | 1 |
| Anzivino, C | 1 |
| Ricchi, M | 1 |
| Loria, P | 1 |
| Kienle, MG | 1 |
| Carulli, N | 1 |
| Gupta, A | 1 |
| Guyomard, V | 1 |
| Zaman, MJ | 1 |
| Rehman, HU | 1 |
| Myint, PK | 1 |
| Rivera Irigoín, R | 1 |
| Nicolau Ramis, J | 1 |
| Terrasa Sagrista, F | 1 |
| Masmiquel Comas, L | 1 |
| Farnier, M | 2 |
| Bortolini, M | 1 |
| Salko, T | 1 |
| Freudenreich, MO | 1 |
| Isaacsohn, JL | 1 |
| Troendle, AJ | 1 |
| Gonasun, L | 1 |
| Corvol, JC | 1 |
| Bouzamondo, A | 1 |
| Sirol, M | 1 |
| Hulot, JS | 1 |
| Sanchez, P | 1 |
| Lechat, P | 1 |
| Kotevoglu, N | 1 |
| Yesilleten, A | 1 |
| Jamal, SM | 1 |
| Eisenberg, MJ | 1 |
| Christopoulos, S | 1 |
| Borghi, C | 1 |
| Dormi, A | 1 |
| Veronesi, M | 1 |
| Sangiorgi, Z | 1 |
| Gaddi, A | 1 |
| Wägner, AM | 1 |
| Ordóñez-Llanos, J | 1 |
| Jorba, O | 1 |
| Pérez, A | 1 |
| Lamendola, C | 1 |
| Abbasi, F | 1 |
| Chu, JW | 1 |
| Hutchinson, H | 1 |
| Cain, V | 1 |
| Leary, E | 1 |
| McLaughlin, T | 1 |
| Stein, E | 1 |
| Reaven, G | 1 |
| Ganda, OP | 1 |
| Fruchart, JC | 1 |
| Duriez, P | 1 |
| Bastani, B | 1 |
| Robinson, S | 1 |
| Heisler, T | 1 |
| Puntney, G | 1 |
| Aridge, D | 1 |
| Lindsey, L | 1 |
| Solomon, H | 1 |
| Garvin, PJ | 1 |
| Simoni, G | 1 |
| Gianotti, A | 1 |
| Ardia, A | 1 |
| Baiardi, A | 1 |
| Civalleri, D | 1 |
| Tenkanen, L | 1 |
| Mänttäri, M | 3 |
| Manninen, V | 6 |
| Gould, AL | 1 |
| Rossouw, JE | 1 |
| Santanello, NC | 1 |
| Heyse, JF | 1 |
| Furberg, CD | 1 |
| Oster, G | 1 |
| Borok, GM | 1 |
| Menzin, J | 1 |
| Heys, JF | 1 |
| Epstein, RS | 1 |
| Quinn, V | 1 |
| Benson, VV | 1 |
| Dudl, RJ | 1 |
| Epstein, A | 1 |
| Lane, DM | 1 |
| Alaupovic, P | 1 |
| Knight-Gibson, C | 1 |
| Dudley, VS | 1 |
| Laughlin, LO | 1 |
| Ramires, JA | 2 |
| Mansur, AP | 2 |
| Solimene, MC | 2 |
| Maranhão, R | 1 |
| Chamone, D | 2 |
| da Luz, P | 1 |
| Pileggi, F | 2 |
| Hautanen, A | 1 |
| Adlercreutz, H | 1 |
| Yuan, J | 1 |
| Tsai, MY | 1 |
| Hunninghake, DB | 2 |
| Bucher, HC | 1 |
| Weinbacher, M | 1 |
| Gyr, K | 1 |
| Betteridge, DJ | 1 |
| Durrington, PN | 1 |
| Fairhurst, GJ | 1 |
| Jackson, G | 1 |
| McEwan, MS | 1 |
| McInnes, GT | 1 |
| Miller, JP | 1 |
| Mir, MA | 1 |
| Reckless, JP | 1 |
| Rees-Jones, DI | 1 |
| Lecerf, JM | 1 |
| Luc, G | 1 |
| Baigts, F | 1 |
| Devulder, B | 1 |
| Demin, AA | 1 |
| Mitrokhin, VE | 1 |
| Rubins, HB | 1 |
| Robins, SJ | 1 |
| Iwane, MK | 1 |
| Boden, WE | 1 |
| Elam, MB | 1 |
| Fye, CL | 1 |
| Gordon, DJ | 1 |
| Schaefer, EJ | 2 |
| Schectman, G | 2 |
| Wittes, JT | 1 |
| Wiklund, O | 2 |
| Angelin, B | 1 |
| Bergman, M | 1 |
| Berglund, L | 1 |
| Bondjers, G | 2 |
| Carlsson, A | 1 |
| Lindén, T | 1 |
| Miettinen, T | 1 |
| Odman, B | 1 |
| Olofsson, SO | 1 |
| Elisaf, MS | 1 |
| Dardamanis, MA | 1 |
| Papagalanis, ND | 1 |
| Siamopoulos, KC | 1 |
| Shepherd, J | 1 |
| Hiatt, J | 1 |
| Gibaldi, M | 1 |
| Kradjan, W | 1 |
| Tikkanen, MJ | 5 |
| Jover, E | 1 |
| Aranda, JL | 1 |
| Nogués, X | 1 |
| del Palacio, A | 1 |
| Rubiés-Prat, J | 1 |
| Akçiçek, F | 1 |
| Ok, E | 1 |
| Duman, S | 1 |
| Kürsad, S | 1 |
| Unsal, A | 1 |
| Alev, M | 1 |
| Atabay, G | 1 |
| Basçi, A | 1 |
| Wright, I | 1 |
| Camejo, G | 1 |
| Lamon-Fava, S | 1 |
| Cole, T | 1 |
| Sprecher, DL | 1 |
| Cilla, DD | 1 |
| Balagtas, CC | 1 |
| Rowan, JP | 1 |
| Black, DM | 2 |
| Muls, E | 1 |
| Van Gaal, L | 1 |
| Autier, P | 1 |
| Vansant, G | 1 |
| Ogawa, H | 1 |
| Tasaka, M | 1 |
| Farmer, JA | 1 |
| Gotto, AM | 1 |
| Kesten, S | 1 |
| Mayne, L | 1 |
| Scavuzzo, M | 1 |
| Maurer, J | 1 |
| Spósito, AC | 1 |
| da Luz, PL | 1 |
| Laakso, M | 1 |
| Ilmonen, M | 1 |
| Helve, E | 2 |
| Kaarsalo, E | 2 |
| Kilkki, E | 1 |
| Saltevo, J | 1 |
| Sanllehy, C | 2 |
| Casals, E | 2 |
| Rodriguez-Villar, C | 1 |
| Zambón, D | 2 |
| Ojuel, J | 1 |
| Ballesta, AM | 1 |
| Ros, E | 2 |
| Bhandari, U | 1 |
| Sharma, JN | 1 |
| Zafar, R | 1 |
| Nagao, K | 1 |
| Yoshida, S | 1 |
| Nakagiri, H | 1 |
| Sakono, M | 1 |
| Sato, M | 1 |
| Imaizumi, K | 1 |
| Rembold, CM | 1 |
| Ismail, MF | 1 |
| Gad, MZ | 1 |
| Hamdy, MA | 1 |
| Tay, JC | 1 |
| Chee, YC | 1 |
| Vigna, GB | 1 |
| Donega, P | 1 |
| Passaro, A | 1 |
| Zanca, R | 1 |
| Cattin, L | 2 |
| Fonda, M | 1 |
| Pauciullo, P | 1 |
| Marotta, G | 1 |
| Fellin, R | 1 |
| Gasparrini, S | 1 |
| Piliego, T | 1 |
| Vergoulas, G | 1 |
| Miserlis, G | 1 |
| Solonaki, F | 1 |
| Imvrios, G | 1 |
| Gakis, D | 1 |
| Papanikolaou, V | 1 |
| Papagiannis, A | 1 |
| Visvardis, G | 1 |
| Takoudas, D | 1 |
| Antoniadis, A | 1 |
| Federman, DG | 1 |
| Hussain, F | 1 |
| Walters, AB | 1 |
| Silva, RM | 1 |
| Santos, FA | 1 |
| Maciel, MA | 1 |
| Pinto, AC | 1 |
| Rao, VS | 1 |
| Napoli, C | 1 |
| Lepore, S | 1 |
| Ambrosio, G | 1 |
| Chiariello, M | 1 |
| Craveri, A | 1 |
| Colombo, L | 1 |
| Citella, C | 1 |
| Pedrazzini, L | 1 |
| Altomare, S | 1 |
| Giavardi, L | 1 |
| Picollo, S | 1 |
| Vignati, A | 1 |
| Lanfredini, M | 1 |
| McKenney, JM | 1 |
| Barnett, MD | 1 |
| Wright, JT | 1 |
| Proctor, JP | 1 |
| D'Agostino, RB | 1 |
| Kannel, WB | 1 |
| Stepanians, MN | 1 |
| D'Agostino, LC | 1 |
| Donzelli, R | 1 |
| Spaziante, R | 1 |
| Cappabianca, P | 1 |
| Tecame, S | 1 |
| de Rosa, N | 1 |
| Mariniello, G | 1 |
| de Divitiis, E | 1 |
| Neuman, MP | 1 |
| Neuman, HR | 1 |
| Neuman, J | 1 |
| Vallés, F | 1 |
| Anguita, M | 1 |
| Anglada, J | 1 |
| Aguirre, C | 1 |
| Fabiani, F | 1 |
| Plaza, L | 1 |
| Soriguer, F | 1 |
| Azanza, JR | 1 |
| Barcina, C | 1 |
| Bobbio, M | 1 |
| Brusca, A | 1 |
| Gambert, P | 1 |
| Girardot, G | 1 |
| Brun, JM | 1 |
| Lalllemant, C | 1 |
| Bertolami, MC | 1 |
| Martinez, TL | 1 |
| Faludi, AA | 1 |
| Pinto, LE | 1 |
| Melo, RS | 1 |
| Bismarck, ZF | 1 |
| Batlouni, M | 1 |
| Gavelli, MS | 1 |
| Vitaliano, E | 1 |
| Rossi, FG | 1 |
| Serra, T | 1 |
| Santini, G | 1 |
| Bernardi, G | 1 |
| Crepaldi, G | 1 |
| Baggio, G | 1 |
| Arca, M | 1 |
| Avellone, G | 1 |
| Avogaro, P | 1 |
| Bittolo Bon, G | 1 |
| Bompiani, GD | 1 |
| Capurso, A | 1 |
| D'Alŏ, G | 1 |
| Ditschuneit, HH | 1 |
| Dreyer, M | 1 |
| Dammann, HG | 1 |
| Ditschuneit, H | 1 |
| Huff, MW | 1 |
| Bertomeu, A | 1 |
| Cusó, E | 1 |
| Tilly-Kiesi, M | 1 |
| Zimetbaum, P | 1 |
| Frishman, WH | 1 |
| Kahn, S | 1 |
| Schulman, KA | 1 |
| Kinosian, B | 1 |
| Jacobson, TA | 1 |
| Glick, H | 1 |
| Willian, MK | 1 |
| Koffer, H | 1 |
| Eisenberg, JM | 1 |
| Walker, JF | 1 |
| Shapiro, DR | 1 |
| Goldberg, R | 1 |
| La Belle, P | 1 |
| Zupkis, R | 1 |
| Ronca, P | 1 |
| Vega, GL | 1 |
| Grundy, SM | 2 |
| Berioli, S | 1 |
| Bentivoglio, M | 1 |
| Conti, R | 1 |
| Osanna, RA | 1 |
| Savino, K | 1 |
| Zollino, L | 1 |
| Corea, L | 1 |
| Romo, M | 1 |
| Koskinen, P | 3 |
| Huttunen, JK | 2 |
| Heinonen, OP | 2 |
| Frick, MH | 2 |
| Pierce, LR | 1 |
| Wysowski, DK | 1 |
| Gross, TP | 1 |
| Langner, NR | 1 |
| Hasselback, PD | 1 |
| Dunkley, GC | 1 |
| Corber, SJ | 1 |
| Tuomilehto, J | 1 |
| Silvasti, M | 1 |
| Uusitupa, M | 1 |
| Aro, A | 1 |
| Jäättelä, A | 1 |
| Lehtonen, A | 1 |
| Malbecq, W | 1 |
| Oksa, H | 1 |
| Pääkkönen, P | 1 |
| Salmi, J | 1 |
| Veharanta, T | 1 |
| Smith, DA | 1 |
| Karmally, W | 1 |
| Brown, WV | 1 |
| Weisweiler, P | 1 |
| Kane, JP | 2 |
| Malloy, MJ | 1 |
| Laustiola, K | 1 |
| Lassila, R | 1 |
| Pellinen, T | 1 |
| Elo, O | 1 |
| Haapa, K | 1 |
| Heinsalmi, P | 1 |
| Helo, P | 1 |
| Kaitaniemi, P | 1 |
| Krause, BR | 1 |
| Newton, RS | 1 |
| Nikkilä, EA | 1 |
| Havel, RJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Exploring the Health Benefits Associated With Daily Pulse Consumption in Individuals With Peripheral Arterial Disease[NCT00755677] | Early Phase 1 | 26 participants (Actual) | Interventional | 2007-03-31 | Completed | ||
| A Multicenter Study Of Nutraceutical Drinks For Cholesterol (Evaluating Effectiveness and Tolerability)[NCT01152073] | 79 participants (Actual) | Interventional | 2009-10-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
17 reviews available for gemfibrozil and Elevated Cholesterol
| Article | Year |
|---|---|
Systematic review on evidence of the effectiveness of cholesterol-lowering drugs.
Topics: Anticholesteremic Agents; Azetidines; Cholestyramine Resin; Coronary Disease; Drug Therapy, Combinat | 2010 |
Differential effects of lipid-lowering therapies on stroke prevention: a meta-analysis of randomized trials.
Topics: Anticholesteremic Agents; Atorvastatin; Cholestyramine Resin; Clofibrate; Colestipol; Gemfibrozil; H | 2003 |
Rhabdomyolysis associated with hydroxymethylglutaryl-coenzyme A reductase inhibitors.
Topics: Cyclosporine; Cytochrome P-450 CYP4A; Dose-Response Relationship, Drug; Drug Interactions; Gemfibroz | 2004 |
The role of lipid management in diabetes.
Topics: Anticholesteremic Agents; Atorvastatin; Diabetes Mellitus; Diabetic Angiopathies; Gemfibrozil; Hepta | 2005 |
Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism.
Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Bezafibrate; Biological Transport; Cholesterol, | 2006 |
Recommendations for treatment of hyperlipidemia in adults. A joint statement of the Nutrition Committee and the Council on Arteriosclerosis.
Topics: Cholesterol; Clofibrate; Coronary Disease; Female; Gemfibrozil; Humans; Hypercholesterolemia; Hyperl | 1984 |
Cholesterol reduction yields clinical benefit. A new look at old data.
Topics: Cholesterol; Cholesterol, Dietary; Clofibrate; Coronary Disease; Dextrothyroxine; Estrogens; Gemfibr | 1995 |
Mechanism of action of fibrates.
Topics: Apolipoproteins B; Bezafibrate; Clofibric Acid; Female; Fenofibrate; Fibric Acids; Gemfibrozil; Huma | 1993 |
Treating elevated cholesterol levels: the great Satan in perspective.
Topics: Animals; Anticholesteremic Agents; Cholestyramine Resin; Clinical Trials as Topic; Coronary Disease; | 1996 |
Selection of appropriate type and intensity of lipid-lowering therapy.
Topics: Cholesterol; Clinical Trials as Topic; Coronary Disease; Diet; Endothelium, Vascular; Enzyme Inhibit | 1995 |
Choosing the right lipid-regulating agent. A guide to selection.
Topics: Anticholesteremic Agents; Cholesterol, LDL; Cholestyramine Resin; Clofibrate; Colestipol; Fenofibrat | 1996 |
Statins in children: what do we know and what do we need to do?
Topics: Atorvastatin; Bezafibrate; Child; Child Welfare; Cost-Benefit Analysis; Drug Approval; Gemfibrozil; | 2001 |
[Evaluation of the therapeutic efficacy of pravastatin in monothereapy and in association with gemfibrozil in hypercholesterolemia associated with moderate hyperglyceridemia].
Topics: Aged; Drug Evaluation; Drug Therapy, Combination; Female; Gemfibrozil; Humans; Hypercholesterolemia; | 1992 |
Effects of gemfibrozil and other fibric acid derivatives on blood lipids and lipoproteins.
Topics: Bezafibrate; Cholesterol, HDL; Clofibric Acid; Diabetes Mellitus, Type 2; Fenofibrate; Fibric Acids; | 1991 |
Reducing high blood cholesterol level with drugs. Cost-effectiveness of pharmacologic management.
Topics: Anticholesteremic Agents; Cholestyramine Resin; Clinical Trials as Topic; Colestipol; Cost-Benefit A | 1990 |
When to treat hyperlipidemia.
Topics: Animals; Arteriosclerosis; Cholesterol; Cholestyramine Resin; Clofibrate; Colestipol; Gemfibrozil; H | 1988 |
Treatment of hypercholesterolemia.
Topics: Animals; Cholestyramine Resin; Clofibrate; Colestipol; Cricetinae; Dogs; Drug Therapy, Combination; | 1986 |
45 trials available for gemfibrozil and Elevated Cholesterol
| Article | Year |
|---|---|
Association between different lipid-lowering treatment strategies and blood pressure control in the Brisighella Heart Study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analysis of Variance; Anticholesteremic Agents; Antihype | 2004 |
Predictors of change in low-density lipoprotein size during lipid-lowering treatment in type 2 diabetes.
Topics: Aged; Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; | 2004 |
Comparative effects of rosuvastatin and gemfibrozil on glucose, insulin, and lipid metabolism in insulin-resistant, nondiabetic patients with combined dyslipidemia.
Topics: Apolipoproteins; Blood Glucose; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combi | 2005 |
Gemfibrozil and Mediterranean diet for patients with high plasma levels of lipoprotein [Lp(a)] and cholesterol--pilot study.
Topics: Aged; Apolipoproteins B; Chemotherapy, Adjuvant; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; En | 1995 |
Some coronary risk factors related to the insulin resistance syndrome and treatment with gemfibrozil. Experience from the Helsinki Heart Study.
Topics: Adult; Blood Glucose; Body Mass Index; Cholesterol, HDL; Coronary Disease; Double-Blind Method; Gemf | 1995 |
A randomized trial to assess effectiveness and cost in clinical practice: rationale and design of the Cholesterol Reduction Intervention Study (CRIS).
Topics: Adult; Aged; Cholesterol, LDL; Coronary Disease; Cost-Benefit Analysis; Costs and Cost Analysis; Fol | 1995 |
Changes in plasma lipid and apolipoprotein levels between heparin-induced extracorporeal low-density lipoprotein precipitation (HELP) treatments.
Topics: Adult; Apolipoproteins; Apolipoproteins A; Apolipoproteins B; Blood Component Removal; Chemical Prec | 1995 |
Effect of gemfibrozil versus lovastatin on increased serum lipoprotein(a) levels of patients with hypercholesterolemia.
Topics: Adult; Aged; Cholesterol; Female; Gemfibrozil; Humans; Hypercholesterolemia; Lipoprotein(a); Lipopro | 1995 |
Changes in composition and distribution of LDL subspecies in hypertriglyceridemic and hypercholesterolemic patients during gemfibrozil therapy.
Topics: Adult; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Female; Gemfibrozil; Humans; Hyperch | 1994 |
Influence of method of reporting study results on decision of physicians to prescribe drugs to lower cholesterol concentration.
Topics: Adult; Attitude of Health Personnel; Decision Making; Female; Gemfibrozil; Humans; Hypercholesterole | 1994 |
Comparison of lipid-lowering effects of low-dose fluvastatin and conventional-dose gemfibrozil in patients with primary hypercholesterolemia.
Topics: Adult; Aged; Analysis of Variance; Anticholesteremic Agents; Double-Blind Method; Fatty Acids, Monou | 1994 |
[Comparison of the efficacy between simvastatin and gemfibrozil in primary hypercholesterolemia].
Topics: Adult; Aged; Double-Blind Method; Female; Gemfibrozil; Humans; Hypercholesterolemia; Hypolipidemic A | 1993 |
[The efficacy of the combined treatment of hypercholesterolemia with gemfibrozil and guar gum].
Topics: Adult; Aged; Combined Modality Therapy; Dietary Fiber; Double-Blind Method; Galactans; Gemfibrozil; | 1993 |
Rationale and design of the Department of Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial (HIT) for secondary prevention of coronary artery disease in men with low high-density lipoprotein cholesterol and desirable low-density lip
Topics: Adult; Aged; Cause of Death; Cholesterol, HDL; Cholesterol, LDL; Clinical Protocols; Coronary Diseas | 1993 |
Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia.
Topics: Adult; Aged; Analysis of Variance; Apolipoproteins B; Cholesterol; Drug Therapy, Combination; Female | 1993 |
[Multicenter comparative study on safety, tolerance, and effectiveness of lovastatin combined or not with cholestyramine, and gemfibrozil combined or not with cholestyramine in the treatment of primary hypercholesterolemia].
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Cholesterol; Cholestyramine Resin; Double-Blind M | 1996 |
Lipid-lowering effects of simvastatin and gemfibrozil in CAPD patients: a prospective cross-over study.
Topics: Adult; Aged; Cholesterol; Combined Modality Therapy; Cross-Over Studies; Diet, Fat-Restricted; Femal | 1996 |
Insoluble complex formation between LDL and arterial proteoglycans in relation to serum lipid levels and effects of lipid lowering drugs.
Topics: Adult; Aged; Anticholesteremic Agents; Arteries; Female; Gemfibrozil; Humans; Hypercholesterolemia; | 1996 |
Effects of regular and extended-release gemfibrozil on plasma lipoproteins and apolipoproteins in hypercholesterolemic patients with decreased HDL cholesterol levels.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Apolipoproteins; Cholesterol, HDL; Cholesterol | 1996 |
[Gemfibrozil reduces elevated lipoprotein (a) levels in hypercholesterolemic patients].
Topics: Analysis of Variance; Anticholesteremic Agents; Chi-Square Distribution; Female; Gemfibrozil; Humans | 1997 |
Treatment of hypercholesterolemia and combined hyperlipidemia with simvastatin and gemfibrozil in patients with NIDDM. A multicenter comparison study.
Topics: Anticholesteremic Agents; Blood Glucose; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes M | 1998 |
Post-prandial effects of gemfibrozil vs simvastatin in hypercholesterolemic subjects with borderline hypertriglyceridemia.
Topics: Adult; Aged; Area Under Curve; Blood Coagulation; Cholesterol; Double-Blind Method; Female; Gemfibro | 1999 |
Combined treatment of hypercholesterolemia of renal transplant allograft recipients with fluvastatin and gemfibrozil.
Topics: Adult; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Creatine Kinase; Creatinine; Drug Therapy, C | 2000 |
[Evaluation of the therapeutic efficacy of pravastatin in monothereapy and in association with gemfibrozil in hypercholesterolemia associated with moderate hyperglyceridemia].
Topics: Aged; Drug Evaluation; Drug Therapy, Combination; Female; Gemfibrozil; Humans; Hypercholesterolemia; | 1992 |
[Changes in lipid status during pravastatin treatment].
Topics: Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Gemfibrozil; Humans; Hyperchol | 1992 |
Comparison of gemfibrozil and lovastatin in patients with high low-density lipoprotein and low high-density lipoprotein cholesterol levels.
Topics: Cholesterol, Dietary; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Female; Gemfibrozil; | 1992 |
A comparison between lovastatin and gemfibrozil in the treatment of primary hypercholesterolemia.
Topics: Adult; Aged; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Female; Gemfibroz | 1992 |
Significant increase of high-density lipoprotein2-cholesterol under prolonged simvastatin treatment.
Topics: Aged; Anticholesteremic Agents; Apolipoproteins; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Do | 1991 |
A multicenter double-blind study comparing lovastatin and gemfibrozil in the treatment of primary hypercholesterolemia.
Topics: Adult; Aged; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Female; Gemfibroz | 1991 |
[Comparison between lovastatin and gemfibrozil in treatment of primary hyperlipidemias].
Topics: Adult; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; Gemfibrozil; Humans; Hypercholestero | 1991 |
[Therapy of hypercholesterolemia and hypertriglyceridemia. Comparison of hypolipemic effects of lovastatin and gemfibrozil].
Topics: Aged; Apolipoproteins B; Cholesterol; Female; Gemfibrozil; Humans; Hypercholesterolemia; Lovastatin; | 1991 |
Pravastatin vs gemfibrozil in the treatment of primary hypercholesterolemia. The Italian Multicenter Pravastatin Study I.
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoproteins B; Cholesterol, HDL; Cholesterol, LDL; Double | 1991 |
[Pravastatin, cholestyramine and gemfibrozil in long-term therapy of primary hypercholesterolemia. An open randomized comparative study].
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol; Cholesterol, HDL; Cholestyramine Resin; Female; | 1991 |
Comparative study of a microporous cholestyramine analogue (filicol) and gemfibrozil for treatment of severe primary hypercholesterolemia. Short- and long-term results.
Topics: Adult; Aged; Apolipoproteins; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Female; Gemf | 1991 |
Hydroxymethylglutaryl coenzyme A reductase inhibitors as monotherapy in the treatment of hypercholesterolemia.
Topics: Bezafibrate; Cholestyramine Resin; Double-Blind Method; Gemfibrozil; Humans; Hydroxymethylglutaryl-C | 1990 |
Comparison of the effects of lovastatin and gemfibrozil on lipids and glucose control in non-insulin-dependent diabetes mellitus.
Topics: Adult; Aged; Aged, 80 and over; Blood Glucose; Cholesterol; Diabetes Mellitus, Type 2; Double-Blind | 1990 |
Primary hypertriglyceridemia with borderline high cholesterol and elevated apolipoprotein B concentrations. Comparison of gemfibrozil vs lovastatin therapy.
Topics: Adult; Aged; Apolipoproteins B; Cholesterol; Gemfibrozil; Humans; Hypercholesterolemia; Hypertriglyc | 1990 |
[Simvastatin versus gemfibrozil in the treatment of primary hypercholesterolemia in hypertensive patients treated with hydrochlorothiazide].
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol; Female; Gemfibrozil; Humans; Hydrochlorothiazide | 1990 |
Reduction in Q wave myocardial infarctions with gemfibrozil in the Helsinki Heart Study.
Topics: Creatine Kinase; Double-Blind Method; Electrocardiography; Gemfibrozil; Humans; Hypercholesterolemia | 1990 |
Management of hyperlipidaemia: the Helsinki Heart Study.
Topics: Coronary Disease; Finland; Gemfibrozil; Humans; Hypercholesterolemia | 1989 |
Guar gum and gemfibrozil--an effective combination in the treatment of hypercholesterolaemia.
Topics: Adult; Aged; Cholesterol; Double-Blind Method; Drug Therapy, Combination; Female; Galactans; Gemfibr | 1989 |
Comparison between lovastatin and gemfibrozil in the treatment of primary hypercholesterolemia: the Finnish Multicenter Study.
Topics: Adult; Double-Blind Method; Female; Finland; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductas | 1988 |
Effects of bezafibrate and gemfibrozil on serum lipoproteins in primary hypercholesterolemia.
Topics: Adult; Aged; Bezafibrate; Cholesterol, LDL; Female; Gemfibrozil; Humans; Hypercholesterolemia; Hypol | 1988 |
Gemfibrozil decreases platelet reactivity in patients with hypercholesterolemia during physical stress.
Topics: Adult; Blood Platelets; Clinical Trials as Topic; Gemfibrozil; Humans; Hypercholesterolemia; Hypolip | 1988 |
Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease.
Topics: Adult; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; | 1987 |
36 other studies available for gemfibrozil and Elevated Cholesterol
| Article | Year |
|---|---|
Gemfibrozil Induces Anemia, Leukopenia and Reduces Hematopoietic Stem Cells via PPAR-α in Mice.
Topics: Anemia; Animals; Cell Count; Gemfibrozil; Hematopoietic Stem Cells; Hypercholesterolemia; Hypolipide | 2020 |
Correlation between plasma levels of 7alpha-hydroxy-4-cholesten-3-one and cholesterol 7alpha-hydroxylation rates in vivo in hyperlipidemic patients.
Topics: Aged; Anticholesteremic Agents; Bezafibrate; Cholestenones; Cholesterol; Cholesterol 7-alpha-Hydroxy | 2008 |
[Rosuvastatin-induced erythema multiforme].
Topics: Anti-Inflammatory Agents; Arthralgia; Drug Hypersensitivity; Drug Substitution; Emergencies; Erythem | 2013 |
Frequency of creatine kinase elevation during treatment with fluvastatin in combination with fibrates (bezafibrate, fenofibrate, or gemfibrozil).
Topics: Adult; Bezafibrate; Creatine Kinase; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Female | 2003 |
Subcutaneous cholesterol nodules: a case report.
Topics: Adult; Cholesterol; Crystallization; Female; Gemfibrozil; Granuloma, Foreign-Body; Humans; Hyperchol | 2003 |
Post-transplant hyperlipidemia: risk factors and response to dietary modification and gemfibrozil therapy.
Topics: Adult; Age Factors; Black People; Blood Glucose; Blood Pressure; Body Weight; Cholesterol; Cholester | 1995 |
Gemfibrozil treatment is associated with elevated adrenal androgen, androstanediol glucuronide and cortisol levels in dyslipidemic men.
Topics: Adrenal Cortex Hormones; Adult; Androgens; Androstane-3,17-diol; Case-Control Studies; Cholesterol, | 1994 |
Choice of cholesterol-lowering drugs.
Topics: Anticholesteremic Agents; Cholestyramine Resin; Clofibrate; Colestipol; Fish Oils; Gemfibrozil; Huma | 1993 |
Lipid abnormalities in chronic uremic patients. Response to treatment with gemfibrozil.
Topics: Adult; Aged; Cholesterol, HDL; Female; Gemfibrozil; Humans; Hypercholesterolemia; Hyperlipidemias; H | 1993 |
Drug therapy for hypercholesterolemia in patients with cardiovascular disease: factors limiting achievement of lipid goals.
Topics: Aged; Anticholesteremic Agents; Cholesterol, LDL; Colestipol; Coronary Disease; Female; Gemfibrozil; | 1996 |
Effects of initial BMI and on-treatment weight change on the lipid-lowering efficacy of fibrates.
Topics: Body Mass Index; Clofibric Acid; Female; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hypercholes | 1997 |
Lipid-regulating action of gemfibrozil in the stroke-prone spontaneously hypertensive rat.
Topics: Animals; Apolipoproteins; Blood Pressure; Cerebrovascular Disorders; Cholesterol; Gemfibrozil; Hyper | 1995 |
Lack of left ventricular dysfunction associated with sustained exposure to hyperlipidemia following lung transplantation.
Topics: Anticholesteremic Agents; Arteriosclerosis; Cholesterol; Cholestyramine Resin; Echocardiography; Fem | 1997 |
Lack of interaction of apolipoprotein E phenotype with the lipoprotein response to lovastatin or gemfibrozil in patients with primary hypercholesterolemia.
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoproteins E; Data Interpretation, Statistical; Drug Int | 1998 |
The protective action of ethanolic ginger (Zingiber officinale) extract in cholesterol fed rabbits.
Topics: Animals; Anticholesteremic Agents; Aorta, Thoracic; Arteriosclerosis; Cholesterol, Dietary; Gemfibro | 1998 |
Gemfibrozil reduces non-high-density lipoprotein cholesterol in exogenously hypercholesterolemic (ExHC) rats fed a high-cholesterol diet.
Topics: Animals; Apolipoproteins; Cholesterol; Cholesterol 7-alpha-Hydroxylase; Cholesterol, Dietary; Feces; | 1998 |
Gemfibrozil to prevent myocardial infarction.
Topics: Cholesterol, LDL; Gemfibrozil; Humans; Hypercholesterolemia; Hypolipidemic Agents; Myocardial Infarc | 1998 |
Study of the hypolipidemic properties of pectin, garlic and ginseng in hypercholesterolemic rabbits.
Topics: Animals; Aorta; Cholesterol; Cholesterol, Dietary; Garlic; Gemfibrozil; Hypercholesterolemia; Hypoli | 1999 |
Drug treatment of hypercholesterolaemia.
Topics: Cholesterol, HDL; Cholesterol, LDL; Female; Gemfibrozil; Humans; Hypercholesterolemia; Hypolipidemic | 1998 |
Choice of lipid-regulating drugs.
Topics: Apolipoproteins; Arteriosclerosis; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Drug Intera | 2001 |
Cholesterol-lowering drugs. Some drugs with demonstrated efficacy but different benefits in primary and secondary prevention.
Topics: Anticholesteremic Agents; Bezafibrate; Cholestyramine Resin; Clinical Trials as Topic; Clofibrate; F | 1999 |
Fatal rhabdomyolysis caused by lipid-lowering therapy.
Topics: Aged; Drug Interactions; Fatal Outcome; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inh | 2001 |
Effect of trans-dehydrocrotonin, a 19-nor-clerodane diterpene from Croton cajucara on experimental hypertriglyceridaemia and hypercholesterolaemia induced by Triton WR 1339 (tyloxapol) in mice.
Topics: Animals; Cholesterol; Croton; Diterpenes; Diterpenes, Clerodane; Gemfibrozil; Hypercholesterolemia; | 2001 |
Vascular microsurgical anastomosis in hypercholesterolemic rats: an experimental study.
Topics: Anastomosis, Surgical; Animals; Carotid Arteries; Cholesterol; Cholesterol, HDL; Fatty Acids, Nonest | 1991 |
[The cholesterol question. Disinformed information].
Topics: Anticholesteremic Agents; Cholesterol; Cholestyramine Resin; Clinical Trials as Topic; Coronary Dise | 1991 |
Effects of gemfibrozil on serum apolipoprotein E distribution in hypercholesterolemic patients.
Topics: Adult; Apolipoproteins E; Female; Gemfibrozil; Humans; Hypercholesterolemia; Male; Middle Aged | 1991 |
Fibrates and HMG-CoA reductase inhibitors.
Topics: Anticholesteremic Agents; Fenofibrate; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhi | 1991 |
Low density lipoprotein density and composition in hypercholesterolaemic men treated with HMG CoA reductase inhibitors and gemfibrozil.
Topics: Adult; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hy | 1991 |
Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy.
Topics: Acute Kidney Injury; Adult; Aged; Creatine Kinase; Drug Interactions; Drug Therapy, Combination; Fem | 1990 |
Attitudes and practices of primary care physicians in the management of elevated serum cholesterol levels.
Topics: Adult; Attitude of Health Personnel; Canada; Cholesterol; Gemfibrozil; Humans; Hypercholesterolemia; | 1989 |
Treating hyperlipidemia, Part III: Drug therapy.
Topics: Aged; Enzyme Inhibitors; Gemfibrozil; Heptanoic Acids; Humans; Hypercholesterolemia; Hyperlipidemias | 1987 |
Lessons from the Helsinki Heart Study. Fibric acid therapy for dyslipidemia.
Topics: Adult; Bile Acids and Salts; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Gemfibrozil; Huma | 1988 |
Current and new therapy for hypercholesterolemia.
Topics: Anticholesteremic Agents; Colestipol; Gemfibrozil; Humans; Hypercholesterolemia; Lovastatin; Niacin; | 1988 |
Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel.
Topics: Adult; Aged; Cholesterol; Cholesterol, LDL; Cholestyramine Resin; Colestipol; Coronary Disease; Diet | 1988 |
Gemfibrozil treatment and the relationship between HDL cholesterol and apoE distribution in cholesterol-fed rats.
Topics: Animals; Apolipoproteins B; Apolipoproteins E; Cholesterol, Dietary; Cholesterol, HDL; Diet; Gemfibr | 1986 |
Current pharmacologic treatment of elevated serum cholesterol.
Topics: Adult; Anticholesteremic Agents; Cholesterol; Cholesterol, LDL; Cholestyramine Resin; Clofibrate; Co | 1987 |